RNAi in Neurodegenerative Diseases—What's the Therapeutic Potential?
Cell. 1998 Dec 23;95(7):1017-26. Abstract Kordower JH, Emborg ME, Bloch J, Ma SY, Chu Y, Leventhal L,
57 RESULTS
You searched 26.
Sort By:
Cell. 1998 Dec 23;95(7):1017-26. Abstract Kordower JH, Emborg ME, Bloch J, Ma SY, Chu Y, Leventhal L,
M, Dohmae N, Takio K, Saido TC, Hashimoto Y. Characterization of alpha 2,6-sialyltransferase cleavage
Radic Biol Med. 2001 Jan 1;30(1):119-28. Abstract 26. Kontush A, Donarski N, Beisiegel U. Resistance of
of hippocampal memory traces. Neuron. 2001 Dec 6;32(5):911-26. Erratum in: Neuron 2002 Jan
changes in Alzheimer's disease and other dementias. Ann N Y Acad Sci. 1997 Sep 26;826:7-24. Review.
Ever since amyloid-β (Aβ) was identified as the major component in amyloid plaques, scientists have been trying to decipher just exactly what the little peptide does. Most researchers would agree that Aβ is toxic to cells, but some are still skeptical. Ev
a long-chain (C26) ceramide synthase. A human homolog of LAG1 can correct the phenotype in yeast, so we do have
this Webinar on 26 October 2006. Readers are invited to submit additional comments by using our
2001 Dec 18;98(26):14979-84. Abstract 6. Hébert SS, Serneels L, Tolia A, Craessaerts K, Derks C,
Peter T. Nelson led this Webinar from 12:00-1:30 p.m. (U.S. Eastern Time) on Friday, 26 October
26;60(4):534-42. Abstract 0 Thursday, March 5, 2009- 00:00 Alzheimer's Disease
slowing down a person’s rate of biological aging—but how to find the requisite variants? In the April 26
Have a topic idea for a webinar? We would love to hear it. Send an email to webinars [at] alzforum [dot] org.